Mon. 25 Mar 2024, 8:04am ET
Benzinga
Biotech, News, General
- Three-part study to evaluate safety, tolerability and pharmacokinetics now underway --
-- RM-718 showed potential to reduce body weight and hyperphagia, no hyperpigmentation
observed in preclinical studies --